Media about us

16 June 2015

New System to Detect Patient's Antibiotic Resistance to Take Just 30 Minutes

Drug Discovery & Development

A new device being developed by medical experts will transform the time it takes to detect antibiotic resistance in patients from several days to just half an hour.

16 June 2015

AstraZeneca R&D executive Morrison to lead cancer firm Syndax

Ben Hirschler / Reuters

AstraZeneca's outgoing chief medical officer and head of global late-stage drug development Briggs Morrison, whose departure from the British drugmaker was announced last week, is to head U.S. cancer firm Syndax Pharmaceuticals.

15 June 2015

Briggs Morrison trades lead role in AstraZeneca R&D for the helm of tiny Syndax

John Carroll / FierceBiotech

Last week, Briggs Morrison was the head of late-stage development and chief medical officer at AstraZeneca with responsibility for leading the turnaround at one of the world's biggest pharma pipelines with thousands of staffers, dozens of clinical-stage programs and a budget that's in the billions. This week, he's moving to a new job as CEO of Syndax Pharmaceuticals, a small biotech based in Waltham, MA, that has a staff of 20, counts its research budget in the millions and has a pipeline with one drug, the histone deacetylase (HDAC) inhibitor entinostat.

15 June 2015

Domain finds unmet need in CF

Steve Edelson / BioCentury

Domain Associates has decided the best way to play the cystic fibrosis space is to find a molecule that can be combined with the ever-increasing number of cocktails emerging from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). To do so, Domain led a $40 million series D round for Celtaxsys Inc. last week, marking its first investment in CF.

11 June 2015

Suprachoroidal injection of triamcinolone acetonide for uveitis proves promising

Nancy Groves / Ophthalmology Times

Patients with noninfectious uveitis who were treated with a single suprachoroidal injection of triamcinolone acetonide in a 6-month phase I/II clinical trial exhibited improvements in best-corrected visual acuity (BCVA), said investigator Debra A. Goldstein, MD.

04 June 2015

NovaMedica To Market Ferring’s IBD Therapies in Russia

Leonor Mateus Ferreira / IDB News Today

The Russian pharmaceutical company NovaMedica and the Swiss biopharmaceutical company Ferring Pharmaceuticals have established a partnership to bring novel gastroenterological drug treatments for inflammatory bowel disease (IBD) to Russia. The two companies announced the signing of an agreement for commercializing a product line of treatments for ulcerative colitis, Crohn’s disease and bleeding fromesophageal varicose.

04 June 2015

NovaMedica and Ferring Pharmaceuticals Bring Innovative Gastroenterological Products From Switzerland to Russia

Yahoo! Finance

NovaMedica, a Russian pharmaceutical company, and Ferring Pharmaceuticals, a Swiss-based global biopharmaceutical company, have signed an agreement, that gives NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.

18 May 2015

New glaucoma devices bring new dimension of treatment

Fred Gebhart / Ophthalmology Times

The loss of visual acuity associated with glaucoma may be an indirect result of increased IOP. But increased IOP is rarely the result of excessive aqueous production. It is usually an insufficiency in aqueous outflow.

07 May 2015

Startup Transcend to submit PMA in second half for glaucoma micro-stent after positive pivotal data

Stacy Lawrence / Fierce Medical Devices

Venture-backed startup Transcend Medical is expecting to submit a PMA for its novel minimally invasive glaucoma surgical implant during the next half of the year. The move comes after the company garnered positive pivotal data, which it has just released.

24 April 2015

Marinus Pharmaceuticals insider Gail M. Farfel Sells 30,000 Shares (MRNS)

Seth Barnet / WKRB News

Marinus Pharmaceuticals (NASDAQ:MRNS) insider Gail M. Farfel sold 30,000 shares of Marinus Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $9.48, for a total value of $284,400.00.